AGTC Genomics Partners with Medilabo Vietnam to Expand Access to Advanced Precision Medicine and Multi-Cancer Early Detection

KUALA LUMPUR / HO CHI MINH CITY – AGTC Genomics is pleased to announce a strategic partnership with Medilabo Vietnam to expand access to advanced genomics and precision medicine solutions in Vietnam.

Through this collaboration, Medilabo Vietnam will gain access to more than 500 advanced genomic and molecular diagnostic tests from AGTC Genomics’ CAP-accredited laboratory, enabling healthcare providers and patients in Vietnam to benefit from world-class precision medicine technologies and internationally aligned laboratory standards.

The partnership covers o-development of broad spectrum of genomic applications, including cancer genomics, hereditary disease screening, reproductive health testing, preventive medicine, pharmacogenomics (PGx), rare disease testing, clinical metagenomics and infectious disease genomics, liquid biopsy, and other advanced precision medicine solutions.

A major highlight of the collaboration is the introduction of AGTC Genomics’ Multi-Cancer Early Detection (MCED) technology, CancerScreenDx™, which is capable of screening for more than 110 cancer types from a single blood draw with superior accuracy. The test utilizes advanced deep sequencing and bioinformatics technologies to detect cancer-associated genomic alterations at an early stage, supporting earlier intervention and improved patient outcomes.

As cancer continues to be one of the leading causes of mortality globally, early detection remains critical in improving survival rates and reducing healthcare burden. Through this partnership, Medilabo Vietnam will be able to offer advanced MCED solutions to clinicians and patients, supporting Vietnam’s growing focus on preventive healthcare and precision medicine.

In addition to oncology applications, the collaboration also aims to strengthen personalized healthcare approaches through pharmacogenomics testing, allowing clinicians to better understand how patients respond to medications based on their genetic profiles. This may help optimize treatment selection, reduce adverse drug reactions, and improve therapeutic outcomes.

The partnership further expands access to advanced infectious disease diagnostics and clinical metagenomics, enabling comprehensive pathogen detection using next-generation sequencing (NGS) technologies. These capabilities are increasingly important for modern healthcare systems managing complex infections and antimicrobial resistance.

Prof. Dr. Leong Chee-Onn, Founder and CEO of AGTC Genomics, said the collaboration reflects a shared commitment to making advanced precision medicine more accessible across Southeast Asia.

“Vietnam is one of the fastest-growing healthcare markets in the region with tremendous potential in precision medicine and genomics. Through our partnership with Medilabo Vietnam, we hope to bring world-class genomic technologies closer to clinicians and patients, while supporting the transition from reactive healthcare toward predictive, preventive, and personalized medicine.”

Medilabo Vietnam is recognized for its commitment to delivering high-quality laboratory and healthcare solutions in Vietnam. By partnering with AGTC Genomics, Medilabo further strengthens its capabilities in advanced molecular diagnostics and next-generation healthcare technologies through access to a comprehensive portfolio of CAP-accredited genomic testing services.

The collaboration also opens opportunities for future clinical research, genomic data development, regional healthcare innovation, and the advancement of precision medicine initiatives tailored to Asian populations.

As Southeast Asia continues to invest in genomics-driven healthcare transformation, the partnership between AGTC Genomics and Medilabo Vietnam represents another important milestone in improving access to advanced molecular diagnostics, early cancer detection, and personalized medicine across the region.